ABBV Dec 2025 210.000 put
| Previous close | 64.23 |
| Open | 63.42 |
| Bid | 70.90 |
| Ask | 73.65 |
| Strike | 210.00 |
| Expiry date | 2025-12-19 |
| Day's range | 62.67 - 64.23 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Reuters
UPDATE 1-US FDA warns of harmful reactions to fake Botox injections
The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
ZacksJohnson & Johnson (JNJ) Q1 Earnings Top Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
